SpacePharma

Company Overview

Snapshot

Founded in June 2013 by Yossi Yamin and Martin Aebi, SpacePharma operates with 11–50 employees. The company has raised $19.98 million across four funding rounds from State of Mind Ventures and European Innovation Council. In January 2026, SpacePharma R&D Israel Ltd was selected by the European Innovation Council Accelerator Programme to build the SPACTORY, the first in-orbit monoclonal antibodies factory outside the atmosphere.

Business overview

SpacePharma specializes in leveraging microgravity for research and development, offering end-to-end miniaturized lab systems equipped with sensors and readers. These systems are designed to operate on various microgravity platforms, including SpacePharma’s nanosatellites, through its mGnify product. The company supports clients through all phases of microgravity experiments, from planning and execution to result analysis, serving the aerospace and pharmaceutical sectors within the Life Sciences & HealthTech industry.

Strategic signal

In January 2026, SpacePharma R&D Israel Ltd was chosen by the European Innovation Council Accelerator Programme to develop SPACTORY, the first in-orbit monoclonal antibodies factory. This selection from 968 proposals highlights significant validation for SpacePharma's innovative approach to space-based manufacturing and signals a major step forward in leveraging microgravity for advanced biopharmaceutical production, potentially accelerating drug discovery and development.

Company Intelligence Q&A

What significant recognition did SpacePharma receive in January 2026?

In January 2026, SpacePharma R&D Israel Ltd was selected by the European Innovation Council Accelerator Programme to build the SPACTORY, which will be the first in-orbit monoclonal antibodies factory outside the atmosphere. This was a competitive selection, chosen from 968 proposals.

What is the nature of SpacePharma's collaboration with Haifa University?

In January 2024, SpacePharma collaborated with Haifa University on cutting-edge space research, utilizing SpacePharma's miniaturized, remotely-controlled labs for microgravity experiments. This partnership, often supported by the Israel Space Agency, focuses on drug discovery, protein crystallization, and developing new tissues for medical advancements, with Haifa researchers exploring DNA structures and antibiotic resistance in space.

What is the SPANCER project, and who are the collaborators?

In December 2024, BSGN (Business in Space Growth Network), SpacePharma, and Roche collaborated on SPANCER. This project uses SpacePharma's microgravity labs (lab-on-a-chip) in space to create consistent, high-quality 3D human tissues for developing better cancer diagnostics and treatments, supported by ESA's BSGN accelerator program.

When did SpacePharma expand its operations to the United States?

In August 2016, SpacePharma expanded its operations to the United States by launching its American subsidiary, SpacePharma, Inc.

What was the focus of the Israeli-Italian collaboration in February 2020?

In February 2020, an Israeli-Italian collaboration focused on studying the behavior of antibacterial materials in space, leveraging SpacePharma's microgravity research capabilities.